Introduction {#section4-2050313X16660485}
============

Iloperidone (Fanapt^®^) is a new second-generation antipsychotic that is approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia.^[@bibr1-2050313X16660485]^ It is not commonly used, and no cases of overdosage have been reported in the literature. We herein report a case of iloperidone overdosage.

Case presentation {#section5-2050313X16660485}
=================

A 27-year-old African-American male with a history of schizophrenia, asthma, and cocaine abuse presented to the hospital less than 1 h after intentionally overdosing on 84 mg of iloperidone after smoking crack cocaine to reduce the severity of the post cocaine nadir. There was no independent confirmation of the overdose medication or amount; however, the transient prolongation of the QTc (see below) seems to serve as independent validation of an overdose of some amount. The patient complained of some shortness of breath, but was not tachypneic, was awake and responsive but lethargic, and was tachycardic in 110 s; vitals were otherwise stable and he had an oxygen (O~2~) saturation of 89% on room air. Electrocardiogram showed a prolonged QTc interval of 527 ms. This dropped to 470 ms (essentially his normal) after 4 days without any arrhythmias. His baseline QTc interval was approximately 440 ms. Since he had a history of developing bronchoconstriction after smoking of cocaine, his respiratory status was a concern. He received intravenous (IV) fluids, oxygen by nasal cannula, nebulizer treatment, and IV steroids. Despite this, his O~2~ saturation dropped to 78% while on oxygen. He ultimately required intubation and mechanical ventilation and was diagnosed with acute respiratory distress syndrome secondary to complications related to his comorbid conditions and the cocaine use. He eventually recovered without obvious sequelae.

Discussion {#section6-2050313X16660485}
==========

There are no published reports of iloperidone overdoses (PubMed search). There are eight known cases of overdoses in the US FDA clinical trials iloperidone database ([Table 1](#table1-2050313X16660485){ref-type="table"}) (product package insert: <http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf>). While the presentation of these cases is fragmented and incomplete, there were no deaths or serious arrhythmias, even with ingestions exceeding 500 mg ([Table 1](#table1-2050313X16660485){ref-type="table"}).

###### 

Summary of information available in the package insert website.

![](10.1177_2050313X16660485-table1)

                 Mg ingested   Duration of ingestion   Highest reported QTc   Tachycardia   Hypotension   Sedation, lethargy   Extra-pyramidal symptoms   Fatality
  -------------- ------------- ----------------------- ---------------------- ------------- ------------- -------------------- -------------------------- ----------
  1              576           All at once             --                     --            --            --                   --                         --
  2              438           4-day period            507                    --            --            --                   \+                         --
  3              292           3-day period                                                                                                               --
  4              48                                                                                                                                       --
  Current case   84            All at once             527                    \+            --            \+                   --                         --

While the package insert reports eight cases of overdose on iloperidone, only fragments of the cases are presented. Missing data are denoted by blank spaces.

The patient reported herein ingested 84 mg immediately before coming to the hospital. This is a dose only 3.5 times higher than the maximum recommended daily dose of 24 mg. In conjunction with this, he smoked crack cocaine. He had previously suffered respiratory failure after smoking cocaine and had previously required mechanical ventilation. Consequently, we believe the respiratory symptoms are probably not related to the iloperidone overdose. However, the initial lethargy and QTc prolongation are probably related to the iloperidone. Iloperidone is known to increase the QTc by a mean of 8.5--9 ms at therapeutic doses (16--24 mg/day).^[@bibr2-2050313X16660485],[@bibr3-2050313X16660485]^ This is similar to the prolongation seen with ziprasidone (9.6 ms at 160 mg/day).^[@bibr2-2050313X16660485],[@bibr3-2050313X16660485]^ The prolongation of QTc is dose-related, so that at 24 mg daily, the mean (range) QTc prolongation is 15.4 (13.4 to 36.0) ms.^[@bibr2-2050313X16660485],[@bibr3-2050313X16660485]^ The observed increase of nearly 87 ms (nearly 2.4 times the maximum reported increase in QT studies) is compatible with the observed dose-related increase of QTc.^[@bibr2-2050313X16660485]^ Animal studies reveal similar findings, but with a maximal prolongation observed even at very high doses (3 mg/kg caused a maximal QTc 42.7 ± 10.2 ms prolongation in guinea pig hearts).^[@bibr4-2050313X16660485]^ Iloperidone is a potent inhibitor of the hERG protein (**h**uman ***E****ther-à-go-go*-**R**elated **G**ene), a subunit of the potassium channel that mediates the inwardly repolarizing potassium current; so as the drug concentration increases, repolarization is delayed and QTc is prolonged.^[@bibr4-2050313X16660485]^

For this individual, his post ingestion course appears to be similar to the cases reported to the FDA ([Table 1](#table1-2050313X16660485){ref-type="table"}): with QTc prolongation without arrhythmia or hypotension, tachycardia, or sedation.

Cocaine use is associated with acute asthma exacerbations, more severe exacerbations with a higher incidence of necessity of assisted ventilation, and a higher prevalence of new-onset bronchospasms.^[@bibr5-2050313X16660485]^ This patient had a previous history of that in the absence of iloperidone. However, it is possible that the iloperidone overdosage contributed to the respiratory distress.

Iloperidone is a strong alpha-2c receptor antagonist, which can prolong QTc, and delay cardiac repolarization. QTc prolongation can be noted at therapeutic dosage.^[@bibr2-2050313X16660485]^ Excessive prolongation with the possibility of arrhythmia is probably the item of greatest concern in iloperidone overdosage.
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